Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Regulatory News (PRTC)

Share Price Information for PureTech (PRTC)

Share Price is delayed by 15 minutes
Get Live Data
126.60    2.40 (1.93%)
Bid:
125.40
Ask:
126.20
Spread: 0.80 (0.638%)
Market Cap: £308.17m
PRTC Live PriceLast checked at - London Stock Exchange

Intraday PureTech Share Chart

Director Declaration

10 Nov 2022 17:00

RNS Number : 0398G
PureTech Health PLC
10 November 2022
 

10 November 2022

 PureTech Health plc

 

Director Declaration

 

Pursuant to Listing Rule 9.6.14(2), PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company") notes that Christopher Viehbacher, a Non-Executive Director and Chair of the Company's Board, has been appointed as President and Chief Executive Officer and a member of the Board of Biogen Inc. (Nasdaq: BIIB) with effect from November 14, 2022. 

 

For further information please contact:

Bharatt Chowrira, PhD, JD, President and Chief Business, Finance and Operating Officer, member of the Board of Directors and Company Secretary: +1 617 482 2333

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RDNEAKFEFFPAFFA
Date   Source Headline
18th Aug 20257:00 amRNSNotice of Results
13th Aug 20255:12 pmRNS-RPRTC's Vedanta Announces VE202 Phase 2 Results
12th Aug 202512:00 pmRNS-RPRTC Launches Celea to Advance Ph3-Ready IPF Drug
5th Aug 20255:30 pmRNSHolding(s) in Company
1st Aug 20257:00 amRNSTotal Voting Rights
17th Jul 202512:05 pmRNS-RPRTC’s Seaport Begins Phase 2b Study in MDD
16th Jul 20257:00 amRNSPureTech Announces Leadership Transition
8th Jul 20255:45 pmRNSDirectorate Change
4th Jul 20255:30 pmRNSPDMR Notification
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
4th Jul 20255:30 pmRNSPDMR Notification RSU Vesting
1st Jul 20257:00 amRNSTotal Voting Rights
26th Jun 20257:00 amRNS-RPRTC'S Vor Announces RemeGen License & $175M PIPE
16th Jun 20255:27 pmRNSResult of AGM
29th May 20255:30 pmRNSHolding(s) in Company
22nd May 202512:00 pmRNS-RPRTC to Present at Jefferies Healthcare Conference
21st May 20257:00 amRNS-RPRTC: IPF Data Support Lung Function Stabilization
9th May 202512:00 pmRNS-RPRTC Publishes Research on Unmet IPF Patient Needs
1st May 202512:00 pmRNS-RPRTC To Present Ph2b IPF Results at ATS Conference
30th Apr 20257:00 amRNSFinal Results
23rd Apr 20257:00 amRNSNotice of Results
11th Apr 20257:00 amRNSHolding(s) in Company
9th Apr 20253:00 pmRNSForm 8.3 PURETECH HEALTH PLC
9th Apr 20257:00 amRNS-RPRTC Appoints Peel Hunt Joint UK Corporate Broker
8th Apr 20252:53 pmGNWInvesco Ltd: Form 8.3 - PureTech Health PLC; Opening Position disclosure
8th Apr 20252:48 pmEQSForm 8.3 - The Vanguard Group, Inc.: PureTech Health plc
8th Apr 20251:15 pmRNSForm 8.3 -PURETECH HEALTH PLC
8th Apr 20251:10 pmRNSForm 8.3 PURETECH HEALTH PLC
8th Apr 202511:40 amGNWForm 8.3 - [PURETECH HEALTH PLC - Opening Disclosure - 07 04 2025] - (CGAML)
8th Apr 202510:00 amRNSForm 8.3 - Puretech Health plc
7th Apr 20255:22 pmRNSRule 2.8 Announcement
7th Apr 20254:27 pmRNSStatement re Possible Offer
11th Mar 202511:05 amRNS-RPRTC's Seaport Adds Finance/Operations Exec to BOD
3rd Mar 20257:00 amRNSTotal Voting Rights
27th Feb 20255:30 pmRNSPDMR Notification RSU Vesting
25th Feb 202512:00 pmRNS-RPRTC Presents at Leerink Partners Healthcare Conf
12th Feb 202512:05 pmRNS-RPRTC's Seaport Publishes New Glyph Platform Data
27th Jan 20257:00 amRNS-RPRTC's Vedanta Publishes Ph2 in Nature Medicine
8th Jan 202512:00 pmRNS-RPureTech to Present at the JP Morgan Conference
6th Jan 20257:00 amRNS-RPureTech Appoints UBS as UK Corporate Broker
16th Dec 20247:00 amRNSPRTC's Ph2b in IPF Successful; New SOC Potential
11th Dec 20245:30 pmRNSHolding(s) in Company
27th Nov 20245:31 pmRNSHolding(s) in Company
27th Nov 20245:30 pmRNSHolding(s) in Company
1st Nov 20247:00 amRNSTotal Voting Rights
31st Oct 20245:00 pmRNSDirector/PDMR Shareholding
21st Oct 20247:00 amRNSPRTC's Seaport Closes $225M Series B Financing
27th Sep 20247:00 amRNSKarXT/Cobenfy Approved by FDA; PRTC Receives $29M
6th Sep 20246:13 pmRNSHolding(s) in Company
28th Aug 20247:01 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.